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Abstract
Individuals diagnosed with social anxiety disorder (SAD) require effective therapeutic
interventions. Due to the nature of SAD, individuals tend to not seek care for their treatment,
leading to the continuation of avoidance behaviors that significantly impact their daily existence.
Psilocybin psychotherapy has the potential to lead to significant changes in the personality
structure of individuals as well as reducing anxious responses to their environment in a relatively
short period of time. Acceptance and commitment therapy (ACT) can serve as the ideal
therapeutic backing to psilocybin as it emphasizes mindfulness and psychological flexibility,
both of which aid in the therapeutic mechanisms of psilocybin. This paper reviews existing
literature surrounding ACT and psilocybin, centering around the potential benefits of a
psilocybin psychotherapy program with ACT as a therapeutic base for individuals with SAD. A
description of a potential psilocybin psychotherapy program is included.
Keywords: mindfulness, psychedelics, third-wave therapy
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Psilocybin Psychotherapy with Acceptance and Commitment Therapy:
A Potential Treatment for Social Anxiety Disorder
Psychedelics are experiencing an explosion in recognition. In recent years, psychedelics,
particularly psilocybin , have been legalized and accepted in various cities, states, and countries
across the world. In 2019 in the United States, Denver, Colorado decriminalized possession of
psilocybin mushrooms. A review panel of the policy found no significant public health or safety
threats occurring from decriminalization, opening the possibility of the further ease of
restrictions of the drug to support therapeutic aims (Hernandez, 2021). In 2020, the state of
Oregon legalized psilocybin psychotherapy, as well as decriminalizing possession of the
substance and legalizing the sale of the substance beginning in 2023 (Oregon Health Authority,
2021). Canada recently approved psilocybin psychotherapy on a case-by-case basis for patients
who have not found success with conventional therapies (Health Canada, 2022). The global
community is beginning to recognize the potential beneficial nature of psilocybin psychotherapy,
thus demonstrating the potential application of psilocybin psychotherapy for individuals with
social anxiety disorder.
Individuals with social anxiety disorder (SAD) require effective treatments for their
condition. SAD is an anxiety disorder marked by fears of public interaction resulting in
avoidance behaviors, such as avoiding doctor’s appointments or refusing to leave their home
(Stein & Stein, 2008). SAD is a major public health concern, with a lifetime prevalence of 12%
(Scheiner, 2006). Due to the nature of the illness, treatment can be difficult to implement
effectively, as patients with SAD are less likely to seek treatment and they make fewer repeat
visits to receive help (Gross et al., 2005). Psilocybin offers an opportunity for therapeutic change
within a relatively small number of sessions (Rucker et al., 2018), reducing the mental distress of
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patients and providing an opportunity for change through a greater understanding of internal
deficits and the opportunity for patients to strengthen their own mental skills through therapeutic
guidance.
Previous research has been conducted on the impact of psilocybin on patients with
general anxiety disorder (Griffiths et al., 2016; Ross et al., 2016;), but none have uniquely
studied the potential benefits of psilocybin psychotherapy for individuals with SAD. As
psilocybin research continues to be heavily regulated, most studies conducted to date are
relatively small-scale (ex Mertens et al., 2020) and focus on populations with serious, potentially
life-threatening, diseases such as terminal cancer patients (Agin-Lebines et al., 2020) or
individuals with addictions (Garcia-Romeau et al., 2015). However, it is possible that individuals
with social anxiety disorder could benefit significantly from psilocybin-backed psychotherapy.
Individuals with social anxiety disorder view themselves as unable to function socially.
They have a concrete view of the world, often seeing themselves as having little control over
their actions and relying on a variety of coping mechanisms to avoid distressing situations, rather
than seeking to change their own behavior (Spinhoven et al., 2014). This negative concrete
model impacts subsequent behavior, as the individual does not want to change from the pattern
of behavior that is comfortable to them, even when that pattern of behavior is detrimental to their
mental health. The prospect of changing these concrete ways of thinking then become an
overwhelming task for those with social anxiety disorder.
The use of psilocybin requires a therapeutic backing to both improve the quality of the
therapy and to ensure the safety of the individual. Acceptance and commitment therapy (ACT)
serves as an ideal backing to investigate the potential benefits of psilocybin, as ACT emphasizes
mindfulness techniques and acceptance of the self (Guss et al., 2020). Differing from traditional
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therapeutic modalities, ACT aims to increase the acceptance of the individual towards their
disorder, rather than viewing their condition as a problem that needs to be solved (Hayes et al.,
2006). These aims are accomplished through mindfulness and cognitive defusion practices, as
well as social skill training and other techniques. ACT can be beneficial for those with anxiety
disorders, as they can learn to accept who they are and then focus on ways to improve their
behavior rather than attempting to solve something that they are told is wrong with them. The
synergistic effects of ACT and psilocybin can provide a unique opportunity for inward reflection
to a degree that is not typical in daily life. In the therapeutic design, a psychologist who is
specifically trained to work with individuals undergoing hallucinogenic experiences
accompanies the participant at all times to ensure the individuals remain focused and direct their
attention to areas that may cause discomfort in daily life. In studies involving psilocybin
psychotherapy with cognitive behavioral therapy (CBT), participants reported feelings of
increased interconnectivity, personal esteem, and a weakening of ego boundaries following
treatment, lending support to the potential benefits of psychotherapy with ACT as the therapeutic
base (Erritzoe et al., 2018; Masden et al., 2020). The psychedelic nature of psilocybin provides a
level of psychological openness and honesty that is difficult to produce in typical interactions,
and these benefits have been shown to last for several months post-treatment.
The aim of this thesis is twofold. First, to examine the potential efficacy and synergistic
effects of combining psilocybin and acceptance and commitment therapy for those with social
anxiety disorder. Second, to provide literary support for further research on psilocybin and
acceptance and commitment therapy as a combined therapeutic intervention for individuals with
social anxiety disorder. Several constraints exist in a potential study design with psilocybin.
Presently, psilocybin remains classified as a Schedule 1 drug (Belouin & Henningfield, 2018),
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and there is a significant cost of treatment and the necessity for trained support staff (GarciaRomeau et al., 2016). Therefore, this thesis will not involve any active trials. The central aim of
this thesis will be to provide support for further research on psilocybin assisted psychotherapy
paired with acceptance and commitment therapy as a therapeutic base for individuals with social
anxiety disorder, thereby expanding the knowledge base of both acceptance and commitment
therapy and psilocybin.
Due to the historical nature of popular opinion on psychedelics such as psilocybin, the
benefits of such drugs are relatively unexplored. There are risks involved using any medication,
and psilocybin is no exception. However, when the set and setting of the environment and the
individual are controlled, the risks are largely mitigated, and the benefits increased. The future of
therapy may rest in substances that serve to supplement therapy, and further research should be
conducted to provide additional opportunities for healing. As mentioned above, no original
research will be conducted, as this thesis aims to demonstrate the potential benefits that could be
possible through further research, as well as contributing to the psychotherapy literature
surrounding psilocybin.
Review of Psilocybin Literature
Historical Nature of Psychedelics
Psychedelics have been used around the world for thousands of years, predating recorded
history. Dried peyote buttons, which contain the psychoactive compound mescaline, have been
found in Native American cave dwellings. These buttons, once carbon dated, were estimated to
have been picked nearly 5,000 years ago, lending support to the awareness of Native Americans
to psychoactive compounds for at least that period of time (El-Seedi et al., 2005). Various
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cultures worldwide have a history of psychedelic use for both recreational and medicinal
purposes. Mesoamerica civilizations have a rich history of psychedelic use, with archaeological,
ethnohistorical, and ethnographic evidence demonstrating the use of psychedelics in religious
ceremonies across several cultures (Carod-Artal, 2011). Mayan cultures consumed psilocybe
cubensis mushrooms, known in their culture as teonanacatl. This consumption of psychedelics
was primarily conducted by religious shamans, who were seen as the link between the physical
and the spiritual world. Religious ceremonies involving psilocybin continue to occur among the
Mayatec people today with rituals that blend the Catholic faith and traditional shamans (CarodArtal, 2011). Shamans use these rituals as an attempt to diagnose and treat participants’ illnesses,
an early example of the therapeutic properties of hallucinogens.
The Western world was introduced to psychedelic compounds in 1897, when Arthur
Heffter isolated mescaline from the peyote cactus (Heffter, 1897). Psychedelic research did not
begin in earnest until Albert Hofmann synthesized LSD-25 as part of an investigation into
compounds derived from ergot alkaloids in 1943 (Rucker, Illiff, & Nutt, 2017). Ergot is a
substance produced by the parasitic fungus Claviceps Purpure and has been named responsible
for multiple episodes of mass poisoning throughout history, with some scholars believing that
ergot poisoning may have resulted in the mass hysteria and strange behaviors demonstrated
during the Salem Witch Trials in 1692 (Woolf, 2000). Lysergic acid diethylamide (LSD) was
initially believed to be ineffective, as few results were demonstrated in animal studies (Hanks &
Gonzales-Maestro, 2012). During a reexamination of the substance, Hoffmann accidentally
contaminated himself with a small dose. Noting unusual psychic effects, Hofmann purposely
consumed 250 mcg of LSD three days later in the first instance of a psychedelic experience from
LSD, thus beginning the modern era of psychedelics (Rucker et al., 2018).
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Since few drugs were available for use alongside the treatment of mental conditions,
psychedelics offered unprecedented insight into the mind. LSD was viewed as a potential path
for change in a variety of mental conditions (Grinspoon & Bakalar, 1997). Psilocybin was first
synthesized in 1959 by Albert Hoffman, the same researcher who synthesized LSD 16 years
previously. This synthesis opened the scientific community to another psychedelic compound
that was both shorter in duration and found in natural fungi (Tylš et al., 2013). The psychedelic
experience resembled some of the symptoms of acute psychosis, including ego-dissolution,
thought disorders, and visual misperceptions, giving researchers insight into the condition that
could not have been obtained otherwise (Rucker et al., 2017). As well, psychedelic intoxication
resulted in increased connection to the unconscious, leading to therapeutic improvements as
individuals came to terms with repressed memories and other elements of the unconscious.
Psychedelic drugs subsequently gained popularity, both in the research field and in
popular culture. Studies were published demonstrating support for the efficacy of psilocybin and
other hallucinogenic drugs on a wide variety of mental conditions. By the end of the 1960s,
hundreds of papers had been published detailing the effects of psychedelic substances such as
mescaline, LSD, and psilocybin (Tylš et al., 2013). Psychotherapy had begun to be conducted
using psychedelics, with therapists offering sessions aided by hallucinogenic experiences.
Psychedelics were considered safe in comparison with known barbiturates, with few lasting
medical effects and low toxicity, even with an overdose amount (Nutt, 2019). However, as the
substances gained popularity, they also came to be associated with a growing counterculture
movement. Led by former Harvard psychology professor Timothy Leary’s cries to “turn on, tune
in, drop out,” the use of psychedelic drugs became popularized as a method to challenge the
popular culture through the creation of a “hippie” subculture. Leary rose to prominence
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following his own psychedelic experience; believing the experience to be transformative, he
returned to Harvard and began conducting psychedelic research on graduate students, eventually
leading to his expulsion following the discovery of underclassmen who were given psychedelic
drugs (Rucker et al., 2018). Following his dismissal from Harvand, O’Leary became the face of
the psychedelic movement, appearing in public debates and frequently inviting others to intake
psychedelics with him. As the movement gained popularity, psychedelics began to be viewed as
a threat to public safety.
The “War on Drugs” in the 1970s and 1980s transformed the culture of the United States
and changed the ways that drugs are viewed in American society (Belouin and Henningfield,
2018). Research opportunities for psychedelic substances were significantly impacted, regardless
of the potential benefits these substances may have provided. Reports of harmful psychedelic
“trips” helped to encourage the DEA to classify psilocybin as a Schedule I drug in 1970,
significantly limiting access to the substance and any subsequent research opportunities (Oram,
2014). Schedule I drugs are defined by the DEA as “drugs with no currently accepted medical
use and a high potential for abuse” (2021). With this classification, the research potential of
hallucinogenic substances was further inhibited, as funding for studies shifted primarily to
private sources, and access to these substances became strictly controlled and expensive to
acquire (Nutt, King, & Nichols, 2013). From the peak of 1,000 clinical papers published between
1950’s and 60’s, research largely died out in the United States and abroad during the 1970’s and
1980’s (Belouin et al., 2018).
A renewed interest into psychedelic research began in the 1990s, as a “new generation of
behavioral health researchers began an in-depth reexamination and rediscovery of the potential
uses of these [psychedelic] substances by applying the latest approaches in clinical research
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development, methods, and procedures'' (Belouin and Henningfield, 2018, p. 10). New research
over the next three decades has revived the search for therapeutic benefits, with several studies
centered around use in populations with OCD, terminal diseases, and major depressive disorder
(Moreno et al., 2006; Griffiths et al., 2016; Watts et al. 2017). Within these therapeutic
environments, psilocybin is ingested in a pill-like capsule, with the dosage determined by the
participants body weight, and monitored by trained support staff in a controlled environment
(Erritzoe et al., 2018). Such controlled psilocybin usage has led to long-term improvements in
various facets of life, indicating the presence of changes beyond that of a drug experience (AginLiebes et al., 2020; Masden et al., 2020; Griffiths et al., 2016).
The Psilocybin Experience
The hallucinogenic experience offered by psilocybin can be difficult to understand
without context. Reality is the most constant state of the human experience, and it can be
challenging to think of reality as something that can be altered and changed by experiences. A
useful analogy for the psychedelic experience is that of a dream, where time, space, and self can
become altered in perception. However, unlike a dream, the process is somewhat controlled, as
the psychedelic experience is influenced by the individual’s mindset and the intentions behind
the experience. The individual’s perception of the nature of the hallucinogenic experience
impacts the subsequent psychedelic experience (Beker, 1967). In a study investigating patient
experiences of psilocybin-assisted psychotherapy, participants reported experiencing “widely
disparate emotions quickly evolving from one into another;” for example, feelings of sadness
quickly followed by feelings of elation (Belser et al., 2017, pg. 366). Highly individualized, the
events of the hallucinogenic experience differ considerably between subjects.
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Past research has been conducted on the effects of psilocybin on different groups of
people. Animal studies have been conducted, but are outside of the scope of the current paper, as
the primary methods for determining anxiety responses are not applicable to investigating social
anxiety and are principally used as markers of psychedelic potential in humans (Hanks and
González-Maeso, 2013). As previously stated, the most apparent consequence of ingesting
psilocybin is the impact the drug has on the individual's view of reality. More than a simple
experience, psilocybin provokes deep introspection and personal meaningfulness. In a study of
hallucinogen-naive adults, psilocybin produced mystic-level experiences that ranked in the top
five of the most significant experiences of the majority of the participants' lives (Griffiths et al.,
2006). The positive effects of psilocybin are not short-lived, with anxiolytic effects persisting for
eight months and six and a half months post-treatment in two separate studies (Griffiths et al.,
2016; Agin-Liebes et al., 2020). The effects last far beyond when psilocybin should be
eliminated from the body, as the half-life of psilocybin is approximately three hours (Passie et
al., 2002). These studies suggest that there is promise for patients with social anxiety disorder to
likewise experience long-lasting reduction of anxious symptoms following psilocybin
psychotherapy.
With any drug, a major concern is the abuse potential of the drug and the safety of
treatment. Given the past public outcry against psychedelics, it is important to understand how
the substance may impact people who ingest it. With psilocybin, there is a low risk of toxicity
(Johnson et al., 2018). In a study of 89 individuals, no detrimental long or short-term effects of
psilocybin on cognitive functioning or emotional processes were revealed (Rucker et al., 2022).
An individual may experience anxiety or confusion during the period of psychedelic
intoxication, but these feelings tend not to last (Studerus et al., 2012). The drug exhibits little
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reinforcing behavior (such as cravings or withdrawals) and may have positive punishment
attributes, such as feelings of anxiety or confusion due to the challenging experiences that may
occur during use (Johnson et al., 2018). The main concern for adverse reactions is the presence
of preexisting conditions, such as significant heart problems or a family history of schizophrenia.
Psilocybin intoxication is marked by a period of increased blood pressure, which could cause
issues with underlying cardiovascular conditions in patients (Hasler et al., 2003). The only
reported fatal overdose from psilocybin occurred in a 24-year-old female who had a heart
transplant 10 years prior, indicating a potential need to exclude any patients with severe cardiac
vulnerability (Johnson et al., 2018). Aspects of the psilocybin experience can resemble
psychosis, potentially causing adverse reactions for those with schizophrenia or with
schizophrenia in their family (Vollenweider et al., 1998). These conditions can and should be
screened for in the population of any study to prevent such adverse effects from occurring during
the process of therapy.
As mentioned prior, the effects of psilocybin are largely subjective, impacted by the socalled “set and setting” of the surrounding environment. First coined by Timothy Leary in 1963,
set and setting refers to the mental state of the individual at the time of the hallucinogenic
experience, as well as the physical location of the individual during the experience (Leary,
Litwin, and Metzner, 1963). The current mood state and psychological distress of the participant
in the previous four weeks was more important for predicting psilocybin response in a metaanalysis of current literature, lending support to the importance of set and setting for psychedelic
experiences (Studerus et al., 2013). It is important to control as much as possible the comfort
level of the participant, as the experience can become frightening or overwhelming if some
aspect of either the individual or the environment is perceived to be negative. With this in mind,
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psychedelic-assisted therapy typically begins with integration sessions focused on educating the
patient about the experience that they will have, communicating about expectations and desires
for the session, and developing therapeutic rapport between the patient and the therapist (Guss,
Krauss, & Slowshower, 2020). These sessions are aimed to relieve any anxieties about the
experience and about the therapeutic process, reducing the potential for any further anxieties to
arise during the psychedelic experience. During therapeutic research sessions, the environment is
closely controlled to ensure there are no external distractions that may cause distress in the
patient. For example, in a study by Griffiths et al. investigating mystical-type experiences during
the course of a dose of psilocybin, participants conducted their drug sessions in an “aesthetic
living-room type environment designed specifically for the study” (2006, p. 270). The purpose is
to make the patient as comfortable as possible, as they will be spending a significant amount of
time in the room they are in during the sessions.
The Effect of Psilocybin on the Brain
The psychedelic effects of psilocybin are theorized to occur due to the agonist effect the
substance has on 5-HT2a receptors inside of the brain. Serotonin, or 5-HT, is a substance
involved in a variety of physiological functions in the body through acting as a hormone or a
neurotransmitter (Lopez-Gimenez and Gonzalez-Maeso, 2019). Fourteen different 5-HT
receptors have been identified through molecular biology techniques. Of the different serotonin
receptors, the receptor 5-HT2a is believed to be associated with the hallucinogenic properties of
psilocybin, as several different lines of evidence support the involvement of the receptor in the
hallucinogenic process. Prior studies have observed a strong correlation between 5-HT2a receptor
affinity and human hallucinogenic potency (Titeler, Lyon, & Glennon, 1988; Sadzot et al., 1989,
Gonzalez-Maeso 2007). As well, the hallucinogenic properties of psilocybin have been shown to
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be blocked following the consumption of a 5-HT2a antagonist, lending support to the importance
of the receptor inside of the hallucinogenic process (Kometer et al., 2013). In a separate study,
the consumption of the 5-HT2a antagonist ketanserin inhibited LSD-induced attribution of
personal relevance to otherwise meaningless stimuli, suggesting the importance of the receptor in
the hallucinogenic process of gaining meaning from otherwise ordinary situations (Preller et al.,
2017).
At a larger systems level, we see important considerations to better understand the
psilocybin’s functional activity. The Default Mode Network (DMN) is a large-scale network in
the brain hypothesized to have a significant role in the creation of ego-identity and the concept of
the self, although the precise function of the network is still not completely understood (Gusnard
et al., 2001). The DMN includes several high-level cognitive areas, including the medial
prefrontal cortex, the posterior cingulate cortex, and the parietal regions (Buckner et al., 2008).
The DMN is named as a result of the activation of the network during states of rest, or the
“default” mode of the brain when no other task is being performed by the participants, and
subsequent deactivation during cognitive task performance (Fox and Raichle, 2007). The DMN
shows strong activation during metacognition tasks, such as retrieving autobiographical
memories, envisioning the future, or thinking of the perspectives of other people (Buckner et al.,
2008). Furthermore, the DMN and other functional networks in the brain have exhibited “inverse
coupling,” where one network deactivates as the other activates and vice versa (Fox and Raichle,
2007). Decreased inverse coupling of the DMN and functional networks of the brain has been
observed in patients with schizophrenia, but it is not known how the decoupling relates to the
symptomatology of this condition (Salvador et al., 2010). The functioning of the DMN seems to
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be associated with the perception of the self, a factor that can be modified during the
consumption of psilocybin (Carhart-Harris et al., 2014).
Changes in functional connectivity between brain areas inside the DMN are shown to be
associated with behavioral changes in participants during psilocybin intoxication. In a study
investigating the efficacy of a psilocybin-assisted mindfulness training program (Smigielski et
al., 2019), a decoupling of the medial prefrontal cortex and the posterior cingulate cortex was
observed following a psilocybin dose. Furthermore, the decoupling of the two brain areas was
associated with the subjective ego dissolution effect during the psilocybin-assisted mindfulness
program (Smigielski et al., 2019). Similarly, the posterior cingulate cortex and the medial
prefrontal cortex demonstrated decreased coupling during psilocybin states in another study,
which was associated with the intensity of the hallucinogenic effects of psilocybin (CarharttHarris et al., 2012) A separate study showed that participants with strongest psilocybin-induced
decoupling in associative networks also demonstrated highest psilocybin-induced coupling in
sensory networks (Preller et al., 2020). This lends support to the idea that psilocybin induces
system-wide functional changes in the brain through the DMN. The involvement of the DMN
during psilocybin intoxication has been shown using multiple imaging techniques, including
fMRI described above and magnetoencephalography (MEG). Using the latter tool, one study
observed large decreases in oscillatory power in areas of the DMN during psilocybin
intoxication, lending additional evidence to the change in functioning of the DMN during
psychedelic use (Muthukumaraswamy et al., 2013). These findings underscore the critical role
that the DMN plays in explaining the functional modulations reported during psychedelic use.
Studies have demonstrated changes in functional connectivity between separate areas of
the brain following psilocybin ingestion. Functional connectivity refers to the shared activation
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of separate brain areas that share functional properties (Biswal, Van Kylen, & Hyde, 1999). One
significant area of the brain that integrates sensory information into a cohesive experience is the
claustrum. Perhaps unsurprisingly, given the nature of the hallucinogenic experience, psilocybin
impacts the functioning of the claustrum during periods of intoxication. In a study by Barrett et
al (2020), psilocybin decreased claustrum connectivity with the auditory cortex, which could be
the root cause of sensory changes that occur during hallucinations. As well, psilocybin resulted
in decreased functional connectivity of the right claustrum with the DMN and auditory networks.
This change in connectivity is theorized to result in alterations of executive function, which
could explain the therapeutic benefits of psilocybin psychotherapy as new paths of thought may
be gained following psychedelic use (Barrett et al., 2020).
Beyond studies looking at the DMN, research has also investigated neural firing patterns
in an active brain under the influence of psilocybin. Previous work has shown that the brain
exhibits system-wide desynchronization of oscillatory rhythms in the cortex during psilocybin
intoxication (Muthukumaraswamy et al., 2013; Preller et al., 2020). This desynchronization
results in dramatic changes to the brain’s functional patterns. Petri et al. (2014) used MEG
images to create a map of the internal connections of the brain during normal consciousness and
during a state of psilocybin ingestion. The functional neural patterns revealed increased
integration between cortical regions during psilocybin state. This was interpreted as neural
networks becoming less specialized and more globally connected in terms of connections
between separate areas of the brain (Petri et al., 2014). These new connections that occur
between separate areas can explain the synesthesia, or experiencing one sense through another
sense, that some individuals experience during psychedelic experiences, as well as the range of
emotions and memories that can be recalled. Furthermore, the investigation by Petri revealed
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homological scaffolding of networks that only appear during the hallucinogenic state.
Homological scaffolding refers to the structures that support global brain organization (Petri et
al., 2014). This unique scaffolding supports the hypothesis that “psilocybin disrupts the normal
organization of the brain with the emergence of strong, topologically long-range functional
connections that are not present in a normal state” (Petri et al., 2014, pg. 7). It is theorized that
through the profound disruption of typical brain activity, detrimental patterns of activity can be
broken, and new more beneficial patterns can be constructed by the individual.
Review of Social Anxiety Disorder
Symptoms of Social Anxiety Disorder
To understand the potential benefits of psilocybin psychotherapy in the treatment of
social anxiety disorder (SAD), it is important to have an understanding of the specific
mechanisms of the disorder. SAD is characterized by an extreme fear of social situations and
interactions (Schneier, 2006). Individuals who experience the disorder often believe that their
own social abilities are significantly deficient when compared to the average individual, leading
to fears of embarrassment or reproach from others in the event of social interaction. In social
settings, individuals may appear to be interacting normally, but they often experience intense
emotional or physical symptoms, including sweating, elevated heart rate, or trouble
concentrating, among other symptoms. These perceived fears can lead to avoidance behaviors,
which in many cases can lead to the avoidance of most interpersonal encounters (Stein & Stein,
2008). Such avoidance behaviors can be extremely disruptive to daily life, creating challenges
whenever public interactions are required. Individuals may skip meetings that require
communication, avoid making connections with others, and believe that they are not capable of
interacting normally. As a result, those with social anxiety disorder earn less wages, are less
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likely to be married, and are more likely to be diagnosed with comorbid depression than their
peers (Katzelnick et al., 2001). Additionally, individuals with SAD may be less likely to seek
primary care due to their anxiety, and even in the event that they do seek care, they make fewer
visits and likely receive less care than individuals with other afflictions (Gross et al., 2005).
Thus, effective interventions are crucial in the lives of those with SAD, with the potential to
create long-lasting behavioral change.
A concrete model of interactions, which refers to the lack of variance in behavior
(Hofmann, 2007), forms throughout the lifetime of those with SAD. This behavior can become
difficult to change, as a routine develops that protects the individual from the detrimental effects
of social interactions. Cognitive factors help to maintain and encourage avoidant behavior. Dr.
Stefan Hofmann (2007), one of the most prominent researchers of SAD, developed a theoretical
model of socially anxious behavior consisting of a ruminative cycle of social interaction. The
individual wants to interact with others, but is apprehensive “in part because they perceive the
social standard (i.e. expectations and social goals) as being high.” (2007). The individual may
hope to convey a certain image but are unsure how to do so due to a lack of planning or
behavioral strategies. In turn, this leads to increased apprehension and self-focused attention.
Individuals with SAD feel that they have no control over their anxious responses in social
situations (Hofmann, 2005). The information processing of those with social anxiety interferes
with social goals, as they feel helpless to stop the increasing anxiety they are feeling. Individuals
with SAD fear social situations in part because they fear a lack of internal control over their
emotions when confronted with a socially threatening situation, which then provokes their
avoidance behaviors (Hoffman et al., 2005). Following a social interaction, the individual
ruminates on the event, which causes distorted negative assumptions that become more concrete
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over time, leading to increased avoidance behaviors. A positive feedback loop is then
established, where the individual experiences less anxiety when avoiding behaviors entirely
(Hofmann, 2007). This ruminative cycle feeds on itself, ensuring that without some sort of
intervention, the avoidant and detrimental behaviors will continue to severely impact the
individual in their daily interactions.
Individuals with social anxiety disorder exhibit abnormal brain activity in response to
threatening situations. The brains of individuals diagnosed with SAD demonstrate increased
activation of the amygdala, which is integral to fear learning and memory, and in the insula,
where perceptual, emotional, and cognitive information is integrated with subjective experiences,
following the viewing of a rejection video (Burklund et al., 2017). The increased neural activity
in the amygdala and insula during a rejection task suggests heightened fear and threat detection
systems in individuals with social anxiety when in situations deemed threatening. This
heightened activity likely results in hypersensitivity to social situations as the individual is
threatened by these contexts. Avoidance behaviors then engage to avoid provoking these
threatened responses in the brain, leading to a cycle of avoidant behaviors that can become
difficult to break.
Traditional treatments for SAD
Most commonly, individuals undergo Cognitive Behavioral Therapy (CBT) to help
reduce avoidance behaviors and increase positive reactions with their surroundings. CBT
remains one of the most researched therapeutic techniques, and many studies have confirmed the
effectiveness of CBT in the reduction of symptoms related to anxious behaviors (Butler et al.,
2006). CBT aims to help those with SAD reduce their personal distress by changing their
cognitive and behavioral responses to anxiety (Craske et al., 2014). The aim of therapy is to
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develop a new network of thoughts and experiences that challenge the old fear-based networks
and memories. These goals are accomplished through various mechanisms, such as exposure
therapy, where the individual is subjected to intentionally disconcerting videos or situations, or
through cognitive restructuring, where the way the individual thinks is challenged by the
therapist and a new system of thought is developed (Arch & Craske, 2008).
Two other popular treatment mechanisms for CBT are social skill training and
desensitization. Social skill training teaches skills for social interactions (Hofmann, 2007), an
aspect that individuals with SAD often lack. The training can take the form of conversation
practices, where the therapist demonstrates proper conversation skills and engages in practice
conversations with the patient. Desensitization aims to remove fear that the individual may feel
in situations by simulating threatening situations in a non-threatening atmosphere (Niles et al.,
2014). Typically, the patient will develop a rank-ordered list of anxiety-provoking situations with
their therapist. Beginning with the least feared situation, the therapist and the patient will
simulate an encounter through role play, imagination, or engaging in the feared situation outside
of session (Heimberg, 2001). Through the contrived exposure, the patient will face a feared
situation in a safe place, aiding the development of the natural conditioning processes of
habituation and extinction.
Although CBT for SAD has been shown to be effective, most patients continue to
demonstrate residual symptoms and impairments after treatment, and a significant percentage do
not respond to treatment at all (Heimburg et al., 2002). In an examination of the effect of CBT on
quality of life (QOL) scores, the scores for the anxious population improved, but still did not
reach the scores of non-anxious individuals (Eng et al., 2001). A separate study involving QOL
scores after 12 weeks of CBT demonstrated improvements in interpersonal domains, but not in
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domains like personal growth (Eng et al., 2005). Therefore, different treatments such as ACT
should be considered, as they may improve quality of life and functioning beyond what CBT
may offer.
Biological changes following CBT
Research has been conducted to identify potential biological bases for the symptom
change that occurs following CBT for individuals with SAD. In a resting state functional
magnetic resonance imaging (fMRI) study, clinical improvement following CBT was predicted
by greater amygdala connectivity with the anterior cingulate cortex (AAC) as well as the medial
prefrontal cortex (mPFC) (Klumpp et al., 2014). Notably, both the AAC and mPFC are members
of a circuit involved in controlling emotion, supporting the notion that connectivity between
these brain areas can be used as a predictor of therapeutic success with CBT. In a separate study,
resting-state regional electroencephalogram (EEG) activity was measured at rest before and after
12 weeks of CBT therapeutic sessions (Moscovitch et al., 2011). Symptom reduction following
treatment was associated with a change in the frontal alpha EEG asymmetry, with greater right
asymmetry revealed pretreatment transitioning to greater left symmetry posttreatment. Greater
pretreatment left asymmetry was also associated with greater improvements in symptom change
following treatment. These results support prior EEG asymmetry-emotion models which
stipulate that in the development of emotions, the brain either chooses to approach or withdraw
(Fox, 1991). More complex emotions are then built upon the choice to either approach or
withdraw, which then leads to the development of different psychopathologies. The shift in
asymmetry from pretreatment to posttreatment supports the notion that therapeutic interventions
result in changes to the functional engagement of brain systems.
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Aside from changes in the brain’s electrical systems, therapeutic interventions have been
shown to be associated with changes to biological neuromarkers in the brain. Regional cerebral
blood flow was assessed through positron emission tomography (PET) using oxygen-15 labeled
water in 18 previously untreated patients with social anxiety disorder during a public speaking
task before and after nine weeks of CBT sessions (Furmark et al., 2002). Improvements of social
anxiety symptom severity in patients were associated with a decreased oxygen-15 water tracer
response bilaterally in the amygdala, hippocampus, and periamygdaloid, rhinal, and
parahippocampal cortices. These brain regions were associated with bodily defense reactions to
threat, demonstrating a biological change that occurs following CBT (Furmark et al., 2002). In a
separate study, the association between dopamine receptor binding and social anxiety symptom
reduction following CBT was investigated (Cervenka et al., 2012). Patients who demonstrated a
significant reduction in social anxiety symptoms demonstrated an increase in dopamine binding
following treatment, signifying a change in brain neurotransmission following a therapeutic
intervention.
Psychotropic Drug Treatments
In addition to strictly therapeutic interventions, individuals with social anxiety disorder
may be prescribed other psychotropic medications. Of the psychotropic drugs, selective
serotonin reuptake inhibitors (SSRIs) such as escitalopram are most prescribed to patients with
social anxiety disorder (Blanco et al., 2003). Baldwin et al. (2016) conducted a meta-analysis of
1615 patients from Japan, North America, and Europe who took part in a double-blind
randomized clinical trial involving escitalopram and a placebo. Escitalopram showed superiority
in efficacy over the placebo, demonstrating a mean decrease from baseline of 41% for the
escitalopram and 27.8% for placebo on the individuals’ responses to the Liebowitz Social
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Anxiety Scale from pretrial to posttrial. However, some researchers suggest that the design of
double-blind placebo studies increases beneficial effects unrelated to the specific treatment of
escitalopram due to the treatment expectations induced by perceived side effects (Moncrieff et
al., 2004). Similarly, a study by Faria et al. (2017) demonstrated that the anxiolytic effects of
escitalopram were susceptible to verbal suggestions provided before the treatment was given.
Members of the population who were given overt messages about the efficacy of their treatment
demonstrated better clinical outcomes, with tripled response rate, greater treatment satisfaction,
and superior improvement in outcome measures. Overall, SSRIs appear to have some use to
some populations, but not demonstrably better than a placebo alone.
Acceptance and Commitment Therapy Review
With psilocybin psychotherapy, the accompanying therapeutic modality is an important
aspect of the experience, as the therapy guides and informs the psychedelic experience through
the therapeutic intentions. Acceptance and commitment therapy (ACT) is an alternative to CBT
that emphasizes mindfulness and psychological flexibility (Hayes et al., 2006). It is a third wave
therapy, based on Relational Frame Theory (RFT) which emphasizes the arbitrary nature of the
relations of events in the minds of individuals and the ability to change the functions of events in
relation to other events (Hayes, Barnes-Holmes, & Roche, 2001). In Western cultures, a focus
exists on avoiding negative emotions and pain (Hayes et al., 2001). This naturally leads to
experiential avoidance of anxiety inducing situations, perpetuating the avoidance processes in
anxiety disorders. Essentially, RFT entails that the relations that people make between two
distinct events, such as the feeling of anxiety and the action of going out in public, are arbitrary
and can be changed when the individual is able to understand the role of language in their lives.
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The ACT model views the source of psychopathology as a fusion between the individual
and their distressing thoughts and the resulting struggle to control their experiences, otherwise
referred to as psychological inflexibility (Hayes et al., 1999). The individual will begin to reduce
contact with the present moment as their attention will primarily be turned towards the avoidance
of anxiety-inducing situations. ACT aims to change the focus of the individual back to the
present moment through reorienting their thinking towards a psychological flexible model of
thoughts and behaviors. ACT focuses on retraining the individual to change their meta-thinking,
or their thinking about their own thoughts. This is accomplished by promoting acceptance
towards what they feel and mindfulness in understanding why their thoughts or actions may be
occurring (Hayes et al., 2006). The therapist works with the individual to acknowledge the
arbitrary connections they have made in their own life and change these connections to promote
mindfulness and acceptance. Through these changes, the individual can learn how to experience
distressing thoughts fully while not being defensive, thereby allowing for the achievement of
personally valued goals (Herbert et al., 2018).
Therapeutic Objectives of Acceptance and Commitment Therapy
The core processes of ACT can be divided into two areas: mindfulness and
acceptance, and commitment and behavior change (Hayes et al., 2006). Mindfulness and
acceptance both involve acceptance of emotions, diffusion of harmful thoughts, and contact with
the present moment. Commitment and behavior change involves self as context, values, and
committed action (Hayes et al., 2006). The end goal is to live a life fully in-the-moment, with
acceptance and understanding towards any emotion or experience that occurs. This goal is
accomplished through increasing cognitive defusion skills, psychoeducation, and values-guided
exposure therapy.
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Cognitive defusion aims to change the way individuals interact with their thoughts,
thereby reducing the negative cognitive load that may have become associated with the thought
or behavior (Niles et al., 2014). Cognitive defusion can take the form of a variety of practices,
examples of which include repetition of a word until it loses its meaning, thinking of thoughts as
separate from the person, or labeling the process of thinking to detach from the emotional
process (Hayes et al., 1999). Semantic satiation, or the process of repeating a word until it loses
meaning, likely has occurred in most people’s daily lives (Arch & Craske, 2008). In ACT, the
individual would repeat anxiety, for instance, until the word has lost its meaning and thus its
personal meaning for the individual. Psychoeducation is the process of educating about
psychological processes, such as where anxieties arise from and strategies to deal with these
anxieties. Values-guided exposure therapy in ACT occurs when individuals are exposed to
threatening situations but are tasked with dealing with those feelings in a way that aligns with
values for life (Ruiz et al., 2020). For example, someone who is undergoing anxious feelings in
the ACT framework embraces the feeling of anxiety without defense, allowing for the moment to
pass in line with the overall value of acceptance. Rather than living a life guided by relief from
psychological pain, ACT emphasizes the importance of a value-guided approach where the
individual is motivated by their internal values to achieve their goals and be able to fully live life.
The type of therapy offered is an important consideration when designing any therapeutic
intervention. For individuals with SAD, CBT is perhaps the most used therapy, while ACT was
developed more recently but is growing in popularity (Landy et al., 2015). CBT and ACT are
both behavior-based therapies but have key differences in their broader intentions for the
therapeutic process. CBT focuses on developing a new associative network of thoughts and
behaviors in order to challenge the fear-based networks that may have developed in the
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individual (Herbert et al., 2018). ACT focuses more on increasing the mindfulness, acceptance,
and cognitive defusion skills in order to promote a lifestyle guided by values (Arch and Craske,
2008). Critiques of CBT suggest that treating mental processes as a problem that needs a solution
may result in an internal battle between the individual and their thoughts (Sloshower et al.,
2020). There is less active engagement of the client in the process of change in CBT, as opposed
to ACT where the individual may be actively engaged in accepting themselves and their
thoughts. Acceptance and commitment therapy has been shown to be a viable alternative to
traditional CBT. In a randomized trial of individuals with SAD, both CBT and ACT groups
outperformed the waitlist group on all outcome measures (Craske et al., 2014). A meta-analysis
of 16 studies comparing the effectiveness of ACT compared to CBT revealed that mean effect
sizes on primary outcomes significantly favored ACT (Ruiz 2012). Although engaging in
different processes, both therapies offer patients an opportunity for improvement in SAD
symptoms, such as distress in social situations or increased conversation skills.
Psilocybin Psychotherapy for Individuals with SAD
Although psilocybin has demonstrated intriguing results in studies across different areas
of behavior, it should not be seen as a “magic-bullet,” with the ability to cure any disorder. The
pattern of behavior in individuals with social anxiety disorder is deeply rooted, and to combat
these behaviors, psilocybin is most effective when accompanied by a therapeutic aid, guiding the
individual through the therapeutic processes and ways of thinking. Psychedelic-assisted therapy
can combine the separate experiences of education on neural mechanisms with lived experiences,
informing and deepening the experiences of both (Sloshower et al., 2020). Furthermore, the
hallucinogenic experience offered by psilocybin causes increased activation of autobiographical
memories, or memory of personal events. Participants who consumed psilocybin in a fMRI
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memory cue task transitioned from lower activity in visual and other sensory regions during
autobiographical memory to increased activity levels (Carhart-Harris et al., 2012). Self-reports
mirror this functional change, with participants reporting more vivid or ‘real’ recalled memories
compared to the control condition, which may be explained by this increased sensory
stimulation. With the combined therapeutic process of ACT and psilocybin, an individual may
become actively engaged in the process of interrupting deeply-held patterns of thought, which
may lead to life-long improvements in their quality of life.
Synergizing Features of ACT with Psilocybin Psychotherapy
As there has been no research directly assessing the impact of psilocybin and acceptance
and commitment therapy on individuals with social anxiety disorder, the purpose of this paper is
to lend support for the further research of the therapeutic intervention. ACT therapy provides an
ideal backing to psilocybin, as the therapy is focused on increasing mindfulness and
psychological flexibility. Psychological flexibility is the capacity to change aspects of the
psyche, a process that may seem impossible to those with SAD. In an analysis of 972 students,
self-reported psychological inflexibility scores were significantly related to both current and
lifetime anxiety disorder diagnoses, providing support to the functionally important role of
psychological inflexibility in the development of anxiety disorders (Levin et al., 2014).
Furthermore, a separate study found that psychological flexibility scores mediated the effect of
insightful experiences on subsequent decreases in depression and anxiety following psychedelic
consumption (Davis, Barrett, & Griffiths, 2020). ACT has been shown to increase psychological
flexibility, with the increases in psychological flexibility mediating changes in outcome (Hayes
et al., 2006) As ACT enhances psychological flexibility and the anxiolytic effect of psilocybin is
impacted by psychological flexibility, it is likely that combining the two will provide synergistic
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benefits leading to greater decreases in social anxiety symptoms in the individual than either
treatment on its own.
Personality Changes Following Psilocybin Dose
Change in personality has a definitive impact on the behavior of an individual. One of the
main tenets of individuals with social anxiety disorder is a tendency to be too internally focused,
criticizing their own performance and in turn not interacting with their environment. A single
dose of psilocybin was associated with long-term, statistically significant increases in openness
and mindfulness (Madsen et al., 2019). Psilocybin was also correlated with a decrease in
neuroticism and an increase in extraversion and openness to experience in a population of people
with major depression (Erritzoe et al., 2018). Neuroticism represents the degree of anxiety,
insecurity, and emotionality in the personality structure of the individual (Erritzoe et al,. 2018).
Extraversion represents how social, optimistic, and talkative individuals are in daily life (Craske
et al., 2014). A survey of 893 subjects demonstrated a positive correlation between lifetime
psychedelic-use and openness, nature-relatedness, and liberal political views, while negatively
predicting authoritarian political views (Nour et al., 2017) Psilocybin can provide long-term
benefits to individuals through impacting personality traits, challenging old assumptions about
life and leading to new ways of thinking.
The contentious nature of psilocybin research necessitates that most current studies are
conducted with smaller sample sizes and focus on elements of the psilocybin experience
(Schmidt et al., 2013; Mertens et al., 2020; Kraehenmann et al., 2016; Mason et al., 2020;
Masden et al., 2019; Kraehenmann et al., 2015), as well as on populations with serious,
potentially life-threatening diseases such as terminal cancer (Agin-Lebines et al., 2020) or
individuals with addictions (Garcia-Romeau et al., 2015). However, there has been some
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research indicating the possible benefits of psilocybin treatment for individuals with social
anxiety. One study demonstrated a reduction in social pain processing following a social
exclusion task in a population that had ingested psilocybin (Preller et al., 2016). Psilocybin was
also correlated with a decrease in neuroticism and an increase in extraversion and openness to
experience in a population of people with major depression (Erritzoe et al., 2018).
Prior studies have demonstrated the ability of psilocybin psychotherapy to provide an
anxiolytic response in patients that lasts beyond the psychedelic experience. In a population of
patients with life-threatening cancer, psilocybin produced substantial and sustained decreases in
depression and anxiety that remained consistent up to eight months post-treatment (Griffiths et
al., 2016). The effects last far beyond when psilocybin should be eliminated from the body, as
the half-life of psilocybin is approximately three hours (Passie et al., 2002). In separate studies,
most patients with life-threatening cancers continued to meet criteria for clinically significant
antidepressant or anxiolytic responses at three months post-treatment (Grob et al., 2013) and six
and a half months post-treatment (Agin-Liebes et al., 2020). Therefore, there is promise for
patients with social anxiety disorder to likewise experience long-lasting reduction of anxious
symptoms following psilocybin psychotherapy.
In general, these changes in personality are theorized to result from the unique ability of
the psychedelic process to compromise the effectiveness of the avoidance strategies of the
individual for reducing aversive states (Wolff et al., 2020). Due to the nature of the psychedelic
experience, individuals are unable to avoid experiencing their emotions, thus enabling psilocybin
to facilitate acceptance-promoting learning processes that can be further bolstered by including
acceptance and commitment therapy as the therapeutic base. As more preliminary research lends
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support to the beneficial nature of psilocybin in the treatment of socially anxious individuals, a
larger scale study on the impact of psilocybin-assisted therapy can be conducted.
Therapeutic benefits for SAD
The therapeutic benefits of psilocybin psychotherapy are strengthened through the
biological changes that are induced following the consumption of psilocybin. Two key areas that
relate to the pathology of anxiety disorders are the amygdala and the serotonin receptor system.
The amygdala is a key structure in emotion-processing circuits in the brain, as it plays a
crucial role in the perception and generation of emotions (Phelps and LeDoux, 2005).
Hyperactivity of the amygdala in response to social threat is consistently observed in individuals
with social anxiety disorder (Phan et al., 2006). Psilocybin may impact amygdalar functioning,
thereby modulating responses to emotional situations. One study revealed decreased amygdala
activity after a psilocybin dose in a population of healthy volunteers (mean age 24.2) compared
to a non-treatment control group (Kraehenmann, 2015). In the study, participants completed a
participants complete a discriminating emotional picture task, with shape discrimination trials
acting as a baseline control condition to return amygdala activity to baseline between alternating
emotional trials. Additionally, those participants showing decreased amygdala activity during the
task also revealed enhanced positive moods. As well, when investigating other patient groups,
we find applicable findings in depression cohorts. Particularly, research with patients with
treatment-resistant major depression revealed a change in the connectivity between the amygdala
and prefrontal cortex following a psilocybin treatment, with decreased prefrontal cortex-right
amygdala connectivity during face processing post-treatment (Mertens et al., 2020). This
decrease was associated with decreased levels of rumination in the individuals. Hence, as
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hyperactivity of the amygdala is a symptom of social anxiety disorder, this result lends support to
the potential beneficial effect psilocybin may have for individuals with social anxiety disorder.
Moving from a behavioral and systems perspective, we can link the effect of psilocybin
use with cellular and molecular findings. Serotonin receptors are implicated in the pathology of
anxiety disorders. In patients diagnosed with social anxiety disorder, PET imaging revealed
significantly lower 5-HT1a receptor binding potential in the amygdala, insula, and anterior
cingulate cortex (Akimova et al., 2009) The biological differences in serotonin receptor binding
potential could be a contributing factor to the negative emotional biases surrounding anxiety
disorders. With the ingestion of psilocybin, serotonin receptors become activated. This activation
is likely associated with biological and functional changes in the limbic circuits implicated in
anxiety disorders and can result in long-term anxiolytic effects in individuals (Vollenweider and
Kometer, 2010; Grob et al., 2011). The anxiolytic effects of psilocybin are theorized to occur due
to a shift in emotional processing through the activation of 5-HT2a and 5-HT1a receptors (AginLiebes et al., 2020). Psilocybin intoxication shifted the negative processing biases of emotional
faces in structural encoding tasks (Schmidt et al., 2013). In a population of healthy participants,
psilocybin enhanced positive mood states, decreased recognition of negative facial expressions,
and increased behavior towards positive relative to negative cues in emotional go/nogo tasks
(Kometer et al., 2012). These effects were not demonstrated after the ingestion of 5-HT2a
antagonist ketanserin, lending support to the importance of the receptor in the anxiolytic effects
of psilocybin (Kometer et al., 2013). Furthermore, in a double-blind study of participants'
reactions to a social exclusion task, individuals who ingested psilocybin reported reduced
feelings of social exclusion (Preller et al., 2016). These reported reduced feelings of social
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exclusion were accompanied by decreased neural responses to the social exclusion in the dorsal
anterior cingulate cortex and the middle frontal gyrus, two key areas for social pain processing.
As described above, the psilocybin experience can involve intense emotions, memories,
and mystical experiences that can result in changes to the personality structure of the individual
as well as changing aspects of the brain’s biological system. Another key attribute of the
psychedelic experience is the ability of psychedelics to induce structural and molecular changes
in the brain. Neuroplasticity is defined as the brain’s ability to modify, change, and adapt
structure and function throughout life through the modification of cellular and molecular
functioning (Voss et al., 2017). In a review of studies (n=20) concerning the biological impact
that result in the anxiolytic effects of psychedelics, de Vos (2021) concluded that a single
administration of a psychedelic resulted in rapid changes in plasticity mechanisms of the brain on
a molecular, neuronal, synaptic, and dendritic level. Among these mechanisms, the increased
dendritic complexity of the brain outlasted the acute effects of the psychedelic. These changes in
neuroplasticity are potentially thought to underlie elements of the clinical effects of psychedelics,
including the anxiolytic response to psychotherapy.
Therapeutic Design of Psilocybin Therapy with ACT
Considering that no actual experimental procedures were conducted involving psilocybin
psychotherapy for the purpose of this paper, a potential schedule of treatment in a psilocybin
therapy program will be described instead. The Yale Manual for Psilocybin-Assisted Therapy of
Depression will serve as a backing for the description of the psilocybin sessions (Guss, Krauss,
& Slowshower, 2020). The manual is the first to provide a guide for psilocybin psychotherapy
treatments for those with major depression. As social anxiety disorder occurs through vastly
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different processes than major depression, the therapeutic process for SAD will emphasize
different aims of treatment than the Yale manual, but follow a similar schedule of programming.
The beginning of the therapeutic process should begin with education on the effects of
psilocybin. As Griffiths et al. demonstrated, proper preparation and interpersonal support
decreased the adverse effects suffered by participants in previous psychedelic-based experiences
(2006). In the first information session, the therapist and the patient should focus on the
experience the patient will undergo. The therapeutic bases of acceptance and commitment
therapy will be discussed, with an emphasis on understanding the role of psychological
flexibility and ways to recognize inflexibility in their own behavior. The first session is also
important for the development of rapport between the therapist and the client. The therapistclient relationship is particularly important in psilocybin-assisted therapy. Hallucinogenic
experiences have the potential to be confusing and anxiety-inducing, as aspects of reality that
were thought to be concrete may become more fluid. The therapist acts as the stable base for the
individual while they are going through a tumultuous event, so it is crucial that the client is able
to trust the therapist and confide in them when they may be undergoing uncomfortable
experiences (Johnson et al., 2008). With anxious populations, it is important that the client and
therapist relationship is developed to the point where the individual will feel comfortable
undergoing the psychedelic experience with the therapist. To ensure the most optimal
experience, the therapist may desire having a preexisting relationship with the client before
beginning the psychedelic therapeutic process. If a relationship does not exist, it is up to the
therapist to use their clinical judgment to decide when the relationship between therapist and
client is stable enough to support psychedelic therapy.
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A second information session before the first psilocybin session will then occur
approximately a week following the initial session, to ensure the patient is fully comfortable with
the therapist, as well as to ensure the therapist is well acquainted with details of the individual’s
life. Although differing from the proposed schedule in the Yale Manual, the second information
session ensures that the patient is fully comfortable. The manual itself states that the amount of
content in the first information session “may be covered more effectively over the course of
several preparatory sessions” (2020). In the second session, the therapist can introduce grounding
techniques such as controlled breathing for dealing with challenging experiences during the
psychedelic process. The therapist will gain a better understanding of the client’s aims in
completing therapy and what experiences may be important in the development of their
pathology. Furthermore, the ACT model can be better understood by the patient, allowing for
deeper introspection in the initial psilocybin session.
Only once the individual feels comfortable with the environment and their therapist
should the first psilocybin session be conducted. The patient should fully understand the process
of a psilocybin dose, as well as the underlying acceptance and commitment model and processes
that are desired through the prior psychoeducation sessions. During the session, the therapist
should note instances where the individual is exhibiting signs of psychological inflexibility, as
well as developing a sense of the model of interactions that the individual may hold in-regards to
social interactions.
The following session will serve as an integration session, where the therapist and the
client work together to analyze the process of the psychedelic experiences and note places where
processes of experiential avoidance or inflexibility could be taking place. Here, the therapist
could begin using acceptance and commitment exercises aimed at decreasing avoidance
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behaviors, such as teaching defusion skills and practicing situations where anxiety may arise.
These integration sessions aim to allow the individual to examine the lessons and feelings that
were aroused during the psilocybin sessions and begin integrating what they felt into their daily
lives. The goal is to create lasting change, and this in part results from a daily commitment to
improving. A second integration session will allow the therapist to determine if practices are
being applied to the client’s daily lives, as well as furthering education on the role of
mindfulness and acceptance in the patient’s own experience.
Following the second integration session, the patient will undergo a second sequence of
psychoeducation sessions, psilocybin sessions, and integration sessions. Through these sessions,
the therapist and the patient will be able to delve deeper into the root cause of the social anxiety,
develop strategies for continual change in behavior, and continue education on necessary
components of acceptance and commitment therapy. After the last integration session, the patient
and the therapist will have an exit session where goals and standards are created to ensure that
behavior change will remain beyond the psilocybin sessions. The patient will have the option of
continuing therapy sessions to encourage the change in mindset that may result from the
psilocybin experience. In the additional therapy sessions, the therapist can continue to use
elements of the psychedelic experience to guide the individual to keep living their life in a way
guided by their personal values.
Conclusion
The field of psychedelic-aided psychotherapy continues to expand, with new studies
being published across the world. Individuals with social anxiety disorder need more effective
treatment, as the nature of the illness entails that those with SAD are less likely to seek treatment
and make fewer return visits to receive aid (Gross et al., 2005). Psilocybin psychotherapy can
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potentially create lasting change in anxiety and personality traits in a small number of sessions
through inducing neuroplasticity in the brain and through the challenging psychedelic experience
of the drug (Agin-Lebines et al., 2020; Madsen et al., 2019; Erritzoe et al., 2018; Griffiths et al.,
2016; de Vos et al., 2021). Acceptance and commitment therapy is an ideal therapeutic backing
for psilocybin psychotherapy as the therapy promotes mindfulness and psychological flexibility,
which are beneficial to increasing the anxiolytic effect of psilocybin (Davis, Barrett, & Griffiths,
2020). The combined attributes of ACT and psilocybin have the potential to have beneficial
anxiolytic effects for populations with SAD. Further research is needed to support the application
of the treatment to individuals, but initial evidence is promising for the potential efficacy of the
treatment.
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